How the Body's Natural Opioid Peptides Influence Alcohol Craving and Intake

The endogenous opioid system — including beta-endorphin, enkephalin, and dynorphin — plays a central role in alcohol craving, intake behavior, and genetic predisposition to alcohol abuse.

Blum, K et al.·Experientia·1989·Preliminary EvidenceReview
RPEP-00104ReviewPreliminary Evidence1989RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

The opioidergic system (beta-endorphin, enkephalin, dynorphin) is involved in both the pharmacological actions of alcohol and the craving/genetic predisposition toward alcohol abuse.

Key Numbers

How They Did This

Literature review synthesizing evidence on neurotransmitter systems — particularly opioid peptides, pineal gland function, and ventral tegmental area activity — and their relationship to ethanol intake in animal models.

Why This Research Matters

Understanding how the body's natural opioid peptides drive alcohol craving could lead to peptide-based interventions for alcohol use disorders.

The Bigger Picture

This review helped establish the scientific basis for why opioid receptor blockers (like naltrexone) can reduce alcohol craving — the same opioid peptide pathways that provide natural reward also drive addictive drinking behavior.

What This Study Doesn't Tell Us

As a review article, this synthesizes existing evidence without presenting new experimental data. Most evidence discussed comes from animal models rather than human clinical studies.

Questions This Raises

  • ?Could targeting specific opioid peptide subtypes provide more effective treatment for alcohol use disorder?
  • ?How do individual genetic differences in opioid peptide expression affect alcohol abuse risk?

Trust & Context

Key Stat:
Three opioid systems linked Beta-endorphin, enkephalin, and dynorphin are all implicated in alcohol craving and intake behavior
Evidence Grade:
This is a narrative review summarizing animal and preclinical evidence. It synthesizes findings but does not present controlled clinical data.
Study Age:
Published in 1989, this is a foundational review. Many of its conclusions have since been validated by clinical naltrexone trials.
Original Title:
Ethanol ingestive behavior as a function of central neurotransmission.
Published In:
Experientia, 45(5), 444-52 (1989)
Database ID:
RPEP-00104

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How do opioid peptides relate to alcohol craving?

The body's natural opioid peptides (beta-endorphin, enkephalin, dynorphin) activate reward pathways in the brain. Alcohol also stimulates these pathways, creating a feedback loop where the opioid system reinforces drinking behavior and can drive craving.

Is this related to why naltrexone helps with alcohol addiction?

Yes. Naltrexone blocks opioid receptors, interrupting the reward signal that alcohol triggers through the opioid peptide system. This review helped establish the scientific basis for that treatment approach.

Read More on RethinkPeptides

Cite This Study

RPEP-00104·https://rethinkpeptides.com/research/RPEP-00104

APA

Blum, K; Briggs, A H; Trachtenberg, M C. (1989). Ethanol ingestive behavior as a function of central neurotransmission.. Experientia, 45(5), 444-52.

MLA

Blum, K, et al. "Ethanol ingestive behavior as a function of central neurotransmission.." Experientia, 1989.

RethinkPeptides

RethinkPeptides Research Database. "Ethanol ingestive behavior as a function of central neurotra..." RPEP-00104. Retrieved from https://rethinkpeptides.com/research/blum-1989-ethanol-ingestive-behavior-as

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.